204 related articles for article (PubMed ID: 10785596)
21. [Expression and significance of programmed cell death ligand-1 in neuroblastoma tissues].
Liao R; Sun XF; Zhen ZZ; Huang DS
Zhonghua Er Ke Za Zhi; 2018 Oct; 56(10):735-740. PubMed ID: 30293276
[No Abstract] [Full Text] [Related]
22. Significance of clinical and biologic features in Stage 3 neuroblastoma: a report from the International Neuroblastoma Risk Group project.
Meany HJ; London WB; Ambros PF; Matthay KK; Monclair T; Simon T; Garaventa A; Berthold F; Nakagawara A; Cohn SL; Pearson AD; Park JR
Pediatr Blood Cancer; 2014 Nov; 61(11):1932-9. PubMed ID: 25044743
[TBL] [Abstract][Full Text] [Related]
23. Event-free survival of children with biologically favourable neuroblastoma based on the degree of initial tumour resection: results from the Pediatric Oncology Group.
Strother D; van Hoff J; Rao PV; Smith EI; Shamberger RC; Halperin EC; Murray KJ; Castleberry RP
Eur J Cancer; 1997 Oct; 33(12):2121-5. PubMed ID: 9516866
[TBL] [Abstract][Full Text] [Related]
24. Biologic factors determine prognosis in infants with stage IV neuroblastoma: A prospective Children's Cancer Group study.
Schmidt ML; Lukens JN; Seeger RC; Brodeur GM; Shimada H; Gerbing RB; Stram DO; Perez C; Haase GM; Matthay KK
J Clin Oncol; 2000 Mar; 18(6):1260-8. PubMed ID: 10715296
[TBL] [Abstract][Full Text] [Related]
25. [Long-term follow-ups of comprehensive therapies for stage 4 neuroblastoma].
Zhang A; Pan C; Ye Q; Zhou M; Chen J; Luo C; Wang J; Tang Y; Xue H; Shen S; Tang J
Zhonghua Yi Xue Za Zhi; 2014 May; 94(20):1547-52. PubMed ID: 25146742
[TBL] [Abstract][Full Text] [Related]
26. Role of urokinase plasminogen activator and its receptor in metastasis and invasion of neuroblastoma.
Li P; Gao Y; Ji Z; Zhang X; Xu Q; Li G; Guo Z; Zheng B; Guo X
J Pediatr Surg; 2004 Oct; 39(10):1512-9. PubMed ID: 15486896
[TBL] [Abstract][Full Text] [Related]
27. Neuroblastoma in older children, adolescents and young adults: a report from the International Neuroblastoma Risk Group project.
Mossé YP; Deyell RJ; Berthold F; Nagakawara A; Ambros PF; Monclair T; Cohn SL; Pearson AD; London WB; Matthay KK
Pediatr Blood Cancer; 2014 Apr; 61(4):627-35. PubMed ID: 24038992
[TBL] [Abstract][Full Text] [Related]
28. Epidemiology of neuroblastoma: analysis of a single institution.
Izbicki T; Mazur J; Izbicka E
Anticancer Res; 2003; 23(2C):1933-8. PubMed ID: 12820482
[TBL] [Abstract][Full Text] [Related]
29. High-dose chemotherapy and autologous haematopoietic stem cell rescue for children with high-risk neuroblastoma.
Yalçin B; Kremer LC; Caron HN; van Dalen EC
Cochrane Database Syst Rev; 2013 Aug; (8):CD006301. PubMed ID: 23970444
[TBL] [Abstract][Full Text] [Related]
30. [Value of prognostic factors in the Austrian A-NB87 Neuroblastoma Study].
Ladenstein R; Ambros PF; Urban C; Ambros IM; Fink FM; Zoubek A; Grienberger H; Schmitt K; Kerbl R; Horcher E; Amann G; Höfler G; Heinzl H; Gadner H; Mutz I
Klin Padiatr; 1996; 208(4):210-20. PubMed ID: 8926686
[TBL] [Abstract][Full Text] [Related]
31. Histopathology (International Neuroblastoma Pathology Classification) and MYCN status in patients with peripheral neuroblastic tumors: a report from the Children's Cancer Group.
Goto S; Umehara S; Gerbing RB; Stram DO; Brodeur GM; Seeger RC; Lukens JN; Matthay KK; Shimada H
Cancer; 2001 Nov; 92(10):2699-708. PubMed ID: 11745206
[TBL] [Abstract][Full Text] [Related]
32. The effect of complete excision on stage III neuroblastoma: a report of the European Neuroblastoma Study Group.
Powis MR; Imeson JD; Holmes SJ
J Pediatr Surg; 1996 Apr; 31(4):516-9. PubMed ID: 8801303
[TBL] [Abstract][Full Text] [Related]
33. Survival outcome of intermediate risk neuroblastoma at Children Cancer Hospital Egypt.
Elzomor H; Ahmed G; Elmenawi S; Elkinaai N; Refaat A; Soliman S; Abdelwahab MA; Zaghloul MS; Fawzy M
J Egypt Natl Canc Inst; 2018 Mar; 30(1):21-26. PubMed ID: 29428371
[TBL] [Abstract][Full Text] [Related]
34. Neuroblastoma messenger RNA is frequently detected in bone marrow at diagnosis of localised neuroblastoma patients.
van Wezel EM; Decarolis B; Stutterheim J; Zappeij-Kannegieter L; Berthold F; Schumacher-Kuckelkorn R; Simon T; Fiocco M; van Noesel MM; Caron HN; van der Schoot CE; Hero B; Tytgat GAM
Eur J Cancer; 2016 Feb; 54():149-158. PubMed ID: 26796600
[TBL] [Abstract][Full Text] [Related]
35. 3-Methoxytyramine: An independent prognostic biomarker that associates with high-risk disease and poor clinical outcome in neuroblastoma patients.
Verly IRN; van Kuilenburg ABP; Abeling NGGM; Goorden SMI; Fiocco M; Vaz FM; van Noesel MM; Zwaan CM; Kaspers GJL; Merks JHM; Caron HN; Tytgat GAM
Eur J Cancer; 2018 Feb; 90():102-110. PubMed ID: 29274926
[TBL] [Abstract][Full Text] [Related]
36. Impact of megatherapy on survival after relapse from stage 4 neuroblastoma in patients over 1 year of age at diagnosis: a report from the European Group for Bone Marrow Transplantation.
Ladenstein R; Lasset C; Hartmann O; Frappaz D; Garaventa A; Klingebiel T; Zucker JM; Coze C; Burdach S; Gadner H
J Clin Oncol; 1993 Dec; 11(12):2330-41. PubMed ID: 8246022
[TBL] [Abstract][Full Text] [Related]
37. Multivariate analysis of risk factors for patients with stage 4 neuroblastoma who were older than 18 months at diagnosis: a report from a single institute in Shanghai, China.
Cai J; Pan C; Tang Y; Chen J; Zhou M; Li B; Xue H; Shen S; Gao Y; Zhang A; Tang J
J Cancer Res Clin Oncol; 2017 Jul; 143(7):1327-1335. PubMed ID: 28283783
[TBL] [Abstract][Full Text] [Related]
38. Neuroblastoma in adolescents: the Italian experience.
Conte M; Parodi S; De Bernardi B; Milanaccio C; Mazzocco K; Angelini P; Viscardi E; Di Cataldo A; Luksch R; Haupt R
Cancer; 2006 Mar; 106(6):1409-17. PubMed ID: 16475209
[TBL] [Abstract][Full Text] [Related]
39. Metastatic neuroblastoma in infants: are survival rates excellent only within the stringent framework of clinical trials?
Di Cataldo A; Agodi A; Balaguer J; Garaventa A; Barchitta M; Segura V; Bianchi M; Castel V; Castellano A; Cesaro S; Couselo JM; Cruz O; D'Angelo P; De Bernardi B; Donat J; de Andoin NG; Hernandez MI; La Spina M; Lillo M; Lopez-Almaraz R; Luksch R; Mastrangelo S; Mateos E; Molina J; Moscheo C; Mura R; Porta F; Russo G; Tondo A; Torrent M; Vetrella S; Villegas JA; Viscardi E; Zanazzo GA; Cañete A
Clin Transl Oncol; 2017 Jan; 19(1):76-83. PubMed ID: 27041689
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of catecholamine metabolites, mIBG scan, and bone marrow cytology as response markers in stage 4 neuroblastoma.
Hero B; Hunneman DH; Gahr M; Berthold F
Med Pediatr Oncol; 2001 Jan; 36(1):220-3. PubMed ID: 11464889
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
